Cosmos Health earnings release, May 22, 2026
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
CHICAGO, IL /
ACCESS Newswire
/ May 21, 2026 /
Cosmos Health Inc.
(“Cosmos Health” or the “Company”)
(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026.
First Quarter 2026 Financial Highlights
Income Statement
Cosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength — over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories.
Balance Sheet
Cosmos Health continued to improve its balance sheet in Q1 2026, with active debt reduction and working capital optimization driving an improvement in the liabilities-to-assets ratio to 68.2% from 71.9% at year-end 2025.
Management Commentary
Greg Siokas, CEO of Cosmos Health, stated:
“Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis, reflecting broad-based commercial momentum across every major division — record distribution volumes at CosmoFarm, continued global expansion of Sky Premium Life, and new contract manufacturing agreements at Cana Laboratories.
This momentum is continuing into Q2 2026, and we are focused on sustaining it well beyond this year. We believe Cosmos Health is entering a new phase of growth, driven by strategic investments across our organization — in personnel, facilities, infrastructure, technology, and AI-driven efficiencies — to support our global expansion plans, strengthen our R&D pipeline, and build the foundation for long-term sustainable value creation. A key pillar of this growth is our entry into the lucrative U.S. nutraceuticals market through the 18 Series platform. Adjusted EBITDA is near breakeven, and we expect it to turn positive as our growth investments drive meaningful returns and revenues continue to scale.
At the same time, we have been disciplined in managing our balance sheet. We reduced total liabilities by $4.5 million in a single quarter, a 9.6% reduction, driven by a substantial reduction in convertible note and credit facility balances. Meanwhile, stockholders' equity increased by 7.6%, our liabilities-to-assets ratio improved by 370 basis points, and our liquidity position remains solid, with $4.3 million in liquid assets including cash of $2.2 million, to support our growth plans.
Q1 2026 is an early indication of what we believe will be a period of significant growth for Cosmos Health, and we look forward to updating our shareholders as this story continues to unfold.”
Financial statements
Income Statement
Three Months Ended March 31, — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| GAAP Figures | REVENUE | 17,927,892 | 13,712,528 |
| GAAP Figures | GROSS PROFIT | 1,381,171 | 2,049,799 |
| GAAP Figures | TOTAL OPERATING EXPENSES | -3,565,350 | -2,882,944 |
| GAAP Figures | GAIN (LOSS) FROM OPERATIONS | -2,184,179 | -833,145 |
| GAAP Figures | TOTAL OTHER INCOME (EXPENSE), NET | -621,244 | 15,048 |
| GAAP Figures | NET GAIN (LOSS) | -2,805,423 | -818,097 |
| NON-GAAP Figures* | ADJUSTED REVENUE | 18,398,493 | 13,712,528 |
| NON-GAAP Figures* | ADJUSTED GROSS PROFIT | 1,851,772 | 2,049,799 |
| NON-GAAP Figures* | ADJUSTED EBITDA | -229,596 | 373,119 |
| NON-GAAP Figures* | ADJUSTED NET INCOME (LOSS) | -996,502 | 277,338 |
Income Statement
Three Months Ended March 31,
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| (in $) | REVENUE | 17,927,892 | 13,712,528 |
| (in $) | Sales discount reversal | 470,601 | |
| (in $) | ADJUSTED REVENUE | 18,398,493 | 13,712,528 |
| (in $) | GROSS PROFIT | 1,381,171 | 2,049,799 |
| (in $) | Sales discount reversal | 470,601 | |
| (in $) | ADJUSTED GROSS PROFIT | 1,851,772 | 2,049,799 |
| (in $) | INCOME (LOSS) BEFORE INCOME TAXES | -2,805,423 | -818,097 |
| Adjustments (add back): | Depreciation and amortization expense | 348,179 | 320,439 |
| Adjustments (add back): | Interest (income) / expense, net | 766,906 | 95,781 |
| Adjustments (add back): | EBITDA | -1,690,338 | -401,877 |
| Adjustments (add back): | Sales discount reversal | 470,601 | |
| Adjustments (add back): | Non-recurring and extraordinary items | 245,116 | 135,621 |
| Adjustments (add back): | Stock-based compensation | 535,786 | 556,611 |
| Adjustments (add back): | Other income (expense), net | -86,161 | 261,730 |
| Adjustments (add back): | Change in fair value of derivative liability & convertible notes | -471,448 | |
| Adjustments (add back): | (Gain) / loss on equity investments & digital assets, net | 453,691 | -3,142 |
| Adjustments (add back): | Foreign currency transaction, net | 313,157 | -175,824 |
| Adjustments (add back): | ADJUSTED EBITDA | -229,596 | 373,119 |
| Adjustments (add back): | Interest income / (expense), net | -766,906 | -95,781 |
| Adjustments (add back): | ADJUSTED NET INCOME (LOSS) | -996,502 | 277,338 |
Balance Sheet
March 31, 2026 — CONDENSED CONSOLIDATED BALANCE SHEET DATA
| March 31, 2026 – (Unaudited) | December 31, 2025 – (Audited) | September 30, 2025 – (Unaudited) | ||
|---|---|---|---|---|
| ASSETS | Cash & cash equivalents | 2,158,921 | 3,459,893 | 4,633,660 |
| ASSETS | Inventory | 5,650,458 | 5,778,142 | 5,683,662 |
| ASSETS | Accounts receivable, prepaid expenses and other current assets | 28,594,752 | 28,662,583 | 25,952,190 |
| ASSETS | Property and equipment, net | 10,280,203 | 10,578,858 | 10,664,820 |
| ASSETS | Goodwill and intangible assets, net | 7,225,011 | 7,569,695 | 7,960,633 |
| ASSETS | Loans receivable | 3,605,388 | 3,633,839 | 7,666,483 |
| ASSETS | Other noncurrent assets | 4,854,278 | 5,794,508 | 6,931,310 |
| ASSETS | TOTAL ASSETS | 62,369,011 | 65,477,518 | 69,492,758 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Accounts payable and accrued expenses | 15,689,061 | 17,412,973 | 15,198,777 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Other current liabilities | 6,701,051 | 6,047,940 | 5,505,549 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Lines of credit | 7,856,208 | 9,177,684 | 7,584,786 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Notes payable | 9,954,812 | 11,485,084 | 15,956,667 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Other non-current and finance/lease liabilities | 2,341,520 | 2,929,208 | 2,112,095 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Stockholders' and mezzanine equity | 19,826,359 | 18,424,629 | 23,134,885 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | TOTAL LIABILITIES AND STOCKHOLDERS'/MEZZANINE EQUITY | 62,369,011 | 65,477,518 | 69,492,758 |